Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
24 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Amyl Therapeutics from Liège, company number BE0758775372, closed financial year 2025 with a result of € -2 million after tax. For that financial year Amyl Therapeutics recorded a gross margin of € -365,861 and equity of € 3.5 million. Compared with financial year 2024, the result moved from € -2.4 million to € -2 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.
€ 3.5 million
▼ 36% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -2 million
▲ 17 % less loss than in 2024
Profit after tax over the fiscal year.
€ 616,658
▼ 73% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -2.4 million.
People and assets in 2025
6.8
▲ 2.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 677,814
▲ 36% vs 2024
€ 99,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 189,410
▼ 1% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 82,023
▼ 89% vs 2024
Loans from banks and other lenders, long and short.
€ 860,759
▲ 119% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 70,046
▲ 28% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -840,592 | € -674,399 | € -872,434 | € -365,861 | ▲ € 506,573 |
| Profit after taxes | € -1,415,300 | € -1,709,641 | € -2,436,601 | € -2,015,273 | ▲ € 421,328 |
| Equity | € 6,208,656 | € 7,999,014 | € 5,562,413 | € 3,547,141 | ▼ 36% |
| Total debts | € 493,938 | € 964,985 | € 2,823,282 | € 3,469,304 | ▲ 23% |
| Cash | € 1,494,636 | € 3,089,277 | € 2,283,118 | € 616,658 | ▼ 73% |
| Retained profit | € -2,414,992 | € -4,124,634 | € -408,876 | € -2,424,149 | ▼ € 2 million |
| Bank debt | € 0 | € 0 | € 729,542 | € 82,023 | ▼ 89% |
| Balance sheet total | € 6,702,593 | € 8,963,999 | € 8,385,696 | € 7,016,445 | ▼ 16% |
| Employees (FTE) | - | - | 4.6 | 6.8 | ▲ 2.2 |
Key figures of Amyl Therapeutics, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Amyl Therapeutics?
What happened at Amyl Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- NOSHAQ PARTNERS SCRL stepped down as director. NBB
- Kenneth BUCKFIRE stepped down as director. NBB
- Christopher MAC NAUGHTON stepped down as director. NBB
- MERIEUX PARTICIPATIONS SAS stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 2 million. Source: NBB ↗
- NOSHAQ PARTNERS SCRL became a director. NBB
- Kenneth BUCKFIRE became a director. NBB
- Christopher MAC NAUGHTON became a director. NBB
In short
From € 1.4 million loss in 2022 to € 2 million loss in 2025.
A new publication or filing at Amyl Therapeutics? We notify you, reason included.
Follow Amyl TherapeuticsDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of VACCIBIO CONSULTING, NOSHAQ comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Amyl TherapeuticsBehind Amyl Therapeutics are VACCIBIO CONSULTING SRL and Swissvention Partners GMBH. The shares are held by VACCIBIO CONSULTING (70%) and NOSHAQ (15.7%).
Directors
According to the 2025 annual accounts
Director · represented by Pierre VANDEPAPELIERE
since 2020
Director · represented by Florent GROS
since 2020
Director · represented by Hugues WALLEMACQ
Also active at: CAUTION MUTUELLE DES METIERS ET NEGOCES, Fonderies J. Marichal Ketin et Cie, DARDENNE, SOGECOM, VITAVERDE.BIO, HAEMERS Technologies, SPACEBEL, NOSHAQ VENTURE +169 more
since 2026 · until 2032
Kenneth BUCKFIRE
Director
since 2026 · until 2032
Christopher MAC NAUGHTON
Director
since 2026 · until 2032
MERIEUX PARTICIPATIONS SAS
Director · represented by CALENDA Valérie
since 2026 · until 2032
Shareholders
15.7%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Boulevard de Patience et Beaujonc 3
4000 Liège
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 24 companies are registered at this address.
All companies at this address →Hyloris Developments
€ 5.1 million revenue · 2025
ONCORADIOMICS same network
€ 2.4 million gross margin · 2025
DERMAX
€ 1.6 million revenue · 2025
Hyloris
€ 384,852 revenue · 2025
Hyloris Pharmaceuticals same network
€ 3.8 million revenue · 2025
+19 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
OVH, FR
DNS
OVH DNS
Domain
Domain
amyltx.com
Registered
2020-11-24
Registrar
OVH, SAS
Expires
2026-11-24
Website info
Features
Security
Details
- Company number
- 0758.775.372
- VAT number
- BE 0758.775.372
- Registered office
- Boulevard de Patience et Beaujonc 3, 4000 Liège
- Names & denominations
- Amyl Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 26 November 2020
- Peppol
- Active · Active since 11 Dec 2025
- Contact
- amyltx.com
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied